Drug intelligence / Profile preview

Kegang Liyan Oral Solution

Development stage: Unknown
Lead developer: PegBio
Administration: Oral

Overview

Kegang Liyan Oral Solution is a Traditional Chinese Medicine (TCM) developed by Guangzhou Wanglaoji Pharmaceutical for the treatment of acute pharyngitis, specifically targeting the Wind-Heat Syndrome according to TCM diagnostic principles. It is formulated as an oral solution and is currently undergoing Phase 3 clinical evaluation in China (CTR20254213) to assess its efficacy and safety in adult patients compared to a placebo. The product is intended to alleviate symptoms such as sore throat, congestion, and inflammation associated with acute pharyngeal infections through a multi-component herbal approach.

Brand names: Kegang Liyan Oral Solution
Other names: 渴刚利咽口服液

Targets

TLR4 (Toll-like receptor 4)MMP9 (Matrix metalloproteinase-9)NF-κB

Beyond the preview

Go deeper on Kegang Liyan Oral Solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kegang Liyan Oral Solution.

Explore the full profile